KOLs' advice on early-stage trials of novel agents for glioblastoma

19 September 2018

Limitation of the blood brain barrier and difficulty in designing reliable early-stage trials has always been the major barriers for developers in formulating novel agents for glioblastoma multiforme (GBM).

As a result, drug makers in the GBM space must bolster the screening procedure for early-stage trials in a more efficient way and demonstrate a clear benefit for patients to push their pipeline agents for the most lethal form of brain cancer through to the finish line, says data and analytics company GlobalData.

Despite the abundance of approvals and launches of novel therapies in the oncology space, no new drugs for GBM were launched since the approval in 2009 of now Roche (ROG: SIX) subsidiary Genentech’s Avastin (bevacizumab).

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK